# The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

> **NCT03301688** · PHASE1 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 38 (actual)

## Conditions studied

- NSCLC

## Interventions

- **BIOLOGICAL:** Toripalimab

## Key facts

- **NCT ID:** NCT03301688
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2018-09-15
- **Final completion:** 2019-12-15
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301688, "The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03301688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*